<DOC>
	<DOCNO>NCT02057211</DOCNO>
	<brief_summary>This project aim evaluate efficacy autologous mesenchymal stem cell treatment preserve insulin production beta-cell mass recently diagnose patient type 1 diabetes mellitus . The hypothesis test increased number circulate mesenchymal stem cell provide immune modulatory property , thereby stop immune process islet cause progressive beta-cell death .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Intervene Development Type 1 Diabetes : Blinded Randomized Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>fast Cpeptide &gt; 0.12 nmol/l within three week diagnosis type 1 diabetes body mass index ( BMI ) &gt; 30 unstable cardiovascular status incl . New York Heart Association ( NYHA ) class III/IV patient know previous malignancy active infection incl . serological evidence infection HIV , Treponema pallidum , hepatitis B ( patient serology consistent previous vaccination history vaccination acceptable ) hepatitis C. immune suppressive treatment woman pregnant nursing , woman physiologically capable become pregnant , unless use effective method contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>